MaaT Pharma presented promising clinical data of MaaT013 at ASH

(Boursier.com) — France’s late-stage biotech company MaAT Pharma presented, on December 10, at the annual meeting of the American Society of Hematology (ASH) in New Orleans (USA), the data of the ongoing program of compassionate access (EAP) in France for MaaT013.

The results of the EAP program, shared during an oral presentation on 10 December by Professor Mohamad Mohty (Head of the Department of Clinical Hematology and Cellular Therapy at Saint-Antoine Hospital and Professor at Sorbonne University), include data on to 81 patients treated with MaaT013, the most advanced high microbial richness and diversity Microbiome Ecosystem TherapyTM (MET) in the Company’s portfolio, intended for emergency use in hospitals.

Results demonstrated an overall response rate (GI-ORR) of 56%, including 30 patients with complete response (37%), 11 patients with very good partial response (14%) and 4 patients with partial response (5%). in patients with GI-aGvH 28 days after initiation of treatment; overall survival at 12 months was 59% in patients who responded to treatment with MaaT013.
An overall response rate of 65% was observed in 31 patients treated with MaaT013 as 3rd-line treatment in patients after failure of 2nd-line treatment with ruxolitinib. In this group that responded to MaaT013 treatment, the 12-month survival rate was 74%. A similar patient population is currently receiving treatment in MaaT Pharma’s pivotal Phase III ARES clinical trial in Europe.

“The clinical benefits we continue to see with MaaT013 are promising and reinforce the potential of our MET treatment to improve survival of vHgv patients when first lines of treatment fail to deliver,” commented Hervé Affagard, general manager and co -founder of MaaT Pharma. “2022 will undoubtedly be seen as a pivotal year marking a turning point for the now more mature microbiota therapeutic sector. We expect acceleration in the sector after the first FDA approval for a microbiota drug in the prevention of infection from C. difficile and promising clinical trials translates into many indications such as infectious diseases and oncology”.

In addition, MaaT Pharma, which announced first patient enrollment for the single-arm, open-label ARES Phase III pivotal study for MaaT013 in March 2022, expects a safety and data review by an independent monitoring committee . ), after enrolling half of the patients, during the first half of 2023.

MaaT Pharma will host a webcast for investors on Monday 12 December at 18:00 CET.